Coeptis Therapeutics to Present SNAP-CAR NK Cell Therapy at ISCT 2024

On May 8, 2024, Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company based in Wexford, Pennsylvania, announced that they will present their pioneering abstract titled "Developing A First-In-Class Universal Allogeneic Snap-Car NK Cell Therapy" at the International Society for Cell & Gene Therapy 2024 conference. The event will take place from May 28 to June 1 in Vancouver, Canada. This prestigious conference is a key event for experts in cell and gene therapy to share innovative research and advancements.

Coeptis Therapeutics, listed on Nasdaq under the ticker COEP, focuses on developing cutting-edge cell therapy platforms aimed at treating cancer, autoimmune, and infectious diseases. The company’s SNAP-CAR technology is designed to serve as a universal CAR therapy. This platform can target multiple antigens by using various adaptors, which may reduce the risk of toxicities and relapse often caused by antigen loss.

In the third quarter of 2023, Coeptis broadened its exclusive license agreement with the University of Pittsburgh. This expansion allowed them to include natural killer (NK) cells in their SNAP-CAR technology. The main aim of the abstract that will be presented at the conference is to discuss how engineered NK cells expressing chimeric antigen receptors (CAR) can be used to enhance their innate anti-tumor functions. This is achieved by specifically activating NK cells in the presence of tumor antigens.

The research, conducted in collaboration with the University of Pittsburgh and Deverra Therapeutics, suggests that allogeneic CAR NK cells could be a safer and more easily accessible alternative to autologous CAR T-cells. The novel SNAP-CAR technology, initially demonstrated in T-cells, is now being developed by Coeptis into a first-in-class universal allogeneic SNAP-CAR NK cell product. This product features a SNAP tag enzyme replacing the antigen-binding domain of a CAR, enabling the attachment of any BG-tagged antibody to create a functional, antigen-specific CAR.

Dave Mehalick, President and CEO of Coeptis Therapeutics, expressed his enthusiasm about the upcoming presentation at ISCT 2024. He highlighted the event's reputation for showcasing groundbreaking ideas and innovations. According to Mehalick, the presentation is a crucial step in advancing the company's mission to develop a universal, allogeneic cell generation platform aimed at treating a range of debilitating diseases.

The oral presentation is scheduled for Thursday, May 30, 2024, at 8 AM. The authors of the abstract include Carrie Stoltzman, Erika von Euw, Braxton Jamison (the presenting author), Emily Hsieh, Kevin Green, Lara Ionescu Silverman, Dan Yerace, Dave Mehalick, and Colleen Delaney. The research institutions involved are Deverra Therapeutics from Seattle, Washington, and Coeptis Therapeutics from Wexford, Pennsylvania.

Coeptis Therapeutics Holdings, Inc. is committed to disrupting traditional treatment paradigms and improving patient outcomes through its innovative cell therapy platforms. The company’s product portfolio includes licensed assets from Deverra Therapeutics, such as an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology (SNAP-CAR) and the GEAR cell therapy and companion diagnostic platforms, in partnership with VyGen-Bio and leading medical researchers at the Karolinska Institutet.

The company’s business model focuses on maximizing the value of its product portfolio through in-license agreements, out-license agreements, co-development relationships, and strategic partnerships. These efforts aim to expand Coeptis’ offerings, particularly in targeting cancer and infectious diseases. Coeptis Therapeutics is headquartered in Wexford, Pennsylvania.